Recent News

• 02.10.2026 - IGC Pharma Announces Equity Research Update by Alliance Global Partners
• 02.09.2026 - IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center
• 02.02.2026 - IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation
• 01.22.2026 - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York
• 01.12.2026 - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia
• 01.06.2026 - Is Neurodegeneration the Root Cause of Alzheimer’s Disease?
• 01.06.2026 - IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
• 01.05.2026 - IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
• 12.19.2025 - IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
• 12.19.2025 - IGC Pharma Leverages AI PlatformMINT-AD to Uncover Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends

Recent Filings

• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 8-K Current report
• 01.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.02.2026 - 8-K Current report
• 12.15.2025 - 8-K Current report
• 12.05.2025 - EFFECT Notice of Effectiveness